GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Haisco Pharmaceutical Group Co Ltd (SZSE:002653) » Definitions » Change In Receivables

Haisco Pharmaceutical Group Co (SZSE:002653) Change In Receivables : ¥0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Haisco Pharmaceutical Group Co Change In Receivables?

Haisco Pharmaceutical Group Co's change in receivables for the quarter that ended in Mar. 2024 was ¥0 Mil. It means Haisco Pharmaceutical Group Co's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Haisco Pharmaceutical Group Co's change in receivables for the fiscal year that ended in Dec. 2023 was ¥-71 Mil. It means Haisco Pharmaceutical Group Co's Accounts Receivable increased by ¥71 Mil from Dec. 2022 to Dec. 2023 .

Haisco Pharmaceutical Group Co's Accounts Receivable for the quarter that ended in Mar. 2024 was ¥798 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Haisco Pharmaceutical Group Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 96.81.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Haisco Pharmaceutical Group Co's liquidation value for the three months ended in Mar. 2024 was ¥-312 Mil.


Haisco Pharmaceutical Group Co Change In Receivables Historical Data

The historical data trend for Haisco Pharmaceutical Group Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haisco Pharmaceutical Group Co Change In Receivables Chart

Haisco Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 160.82 16.13 -45.88 -191.11 -70.94

Haisco Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Haisco Pharmaceutical Group Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Haisco Pharmaceutical Group Co  (SZSE:002653) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Haisco Pharmaceutical Group Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=797.927/752.134*91
=96.81

2. In Ben Graham's calculation of liquidation value, Haisco Pharmaceutical Group Co's accounts receivable are only considered to be worth 75% of book value:

Haisco Pharmaceutical Group Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=1509.278-2559.066+0.75 * 797.927+0.5 * 278.728
=-312

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Haisco Pharmaceutical Group Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Haisco Pharmaceutical Group Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Haisco Pharmaceutical Group Co (SZSE:002653) Business Description

Traded in Other Exchanges
N/A
Address
No. 17, Sanxiang Avenue, Shannan District, Tibet Autonomous Region, Zetang, CHN, 856000
Haisco Pharmaceutical Group Co Ltd is a pharmaceutical company based in China. It is mainly engaged in the research, development, manufacture, and sale of drugs for liver disease. Its product portfolio includes parenteral nutrition drugs, antibiotics, anesthetic agents, digestive system drugs and tumour adjuvant drug series. The company's products are being used in first rank hospitals in China.
Executives
Fan Xiu Lian Directors, executives
Zheng Wei Directors, executives
Wang Meng Secretary Dong
Wang Jun Min Directors, executives
Deng Xiang Directors, executives
Liu Han Bing Supervisors
Zhang Xiao Xu Supervisors
Tan Hong Executives
Shen Ping Director
Liang Yong Supervisors
Chen Long Independent director
Duan Qing Liang Supervisors

Haisco Pharmaceutical Group Co (SZSE:002653) Headlines

No Headlines